TAIWO AJANI: Open Payments
NPI 1982170213 · LAUREL, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,837 in 71 payments from 11 companies in 2025. Trend: 2023 $847 · 2024 $1,034 · 2025 $1,837
Food & beverage: $1,833Education: $4
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $355 |
| ABBVIE INC. | 13 | $317 |
| Alkermes, Inc. | 13 | $284 |
| Otsuka America Pharmaceutical, Inc. | 2 | $153 |
| Supernus Pharmaceuticals, Inc. | 10 | $151 |
| Neuronetics, Inc. | 3 | $146 |
| E.R. Squibb & Sons, L.L.C. | 2 | $140 |
| Axsome Therapeutics, Inc. | 7 | $136 |
| Neurocrine BioSciences, Inc. | 1 | $114 |
| Lundbeck LLC | 1 | $22 |
Products named: CAPLYTA, VRAYLAR, REXULTI, Qelbree, ARISTADA, NEUROSTAR TMS THERAPY SYSTEM, COBENFY, Auvelity.
Industry payments across MD — which companies pay providers there.
